Praxis Precision Medicines: Breakthrough Neurology Pipeline and Regulatory Momentum Support Upside and Buy Rating
I'm PortAI, I can summarize articles.
Francois Brisebois from LifeSci Capital has maintained a Buy rating on Praxis Precision Medicines, raising the price target to $534.00. This decision is based on the company's advancing neurology pipeline and recent regulatory momentum, particularly the FDA's Breakthrough Therapy Designation for ulixacaltamide. Brisebois anticipates significant market uptake and a favorable long-term revenue outlook, supported by positive clinical data and upcoming NDA filings. Jefferies also maintains a Buy rating with a $450.00 price target, reflecting confidence in the company's growth potential.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments